FDA Approves Adjuvant Sunitinib for High-Risk RCC

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.11/30/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news